- CA$193.87m
- CA$188.07m
- CA$43.05m
Brief: BioSyent reports Q2 earnings per share C$0.11
Brief: Biosyent extends in-license agreement for cathejell
Brief: Biosyent Q4 earnings per share C$0.08
Brief: Biosyent Q3 EPS C$0.08
Brief: BioSyent pharma international signed exclusive license, supply agreement with European partner for new women's health product
Brief: Biosyent signs agreement for new women's health product
Brief: Biosyent Q2 fully diluted EPS $0.07
Brief: BioSyent Q1 earnings per share C$0.07
Brief: Biosyent signs distribution agreement for new cardiovascular products
Brief: Biosyent BioSyent Pharma wins Canada approval for Aguettant System
Brief: Biosyent releases Q4 and full year 2015 results